Capecitabine
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-CAPECITABINE |
|---|---|
| Type | Drug |
| Aliases | XelodaКапецитабін |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | DIS-CRC DIS-ESOPHAGEAL DIS-GASTRIC DIS-PDAC |
| Sources | SRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025 |
Drug Facts
| Class | Oral fluoropyrimidine prodrug |
|---|---|
| Mechanism | Oral prodrug of 5-FU; converted via 3-step metabolism (carboxylesterase → cytidine deaminase → thymidine phosphorylase, the latter enriched in tumor tissue → tumor-selective activation). Replaces continuous-infusion 5-FU in CAPOX, neoadjuvant rectal CRT, monotherapy elderly adjuvant. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Warnings
- Warfarin interaction (bleeding — monitor INR weekly)
- DPD-related toxicity
Notes
HFS prophylaxis: emollient creams (urea 10-20%), avoid friction and pressure on hands/feet, pre-emptive dose-hold at Grade 2 with resumption at lower dose. Renal dose adjustment is mandatory and often missed: CrCl 30-50 → 75% dose; CrCl <30 contraindicated. Hofheinz 2012 (rectal CRT): capecitabine non-inferior to infusional 5-FU with patient-friendlier oral schedule (no central line / pump). DPD deficiency screening (DPYD genotyping or uracilemia level) increasingly recommended pre-treatment in EU per EMA 2020 — pre-emptive dose adjustment for partial deficiency, contraindicated in complete deficiency. Warfarin INR monitoring weekly initially (CYP2C9 inhibition). Common combinations: CAPOX (capecitabine + oxaliplatin), CAPIRI / CAPEFOX, capecitabine + trastuzumab in HER2+ mBC, X-RT for rectal/gastric. UA: generic available, широко reimbursed under НСЗУ.
Used By
Drug
DRUG-CAPECITABINE-BREAST- Capecitabine (breast indication entry)
Regimens
REG-CAPE-BEV-MAINTENANCE- Capecitabine + Bevacizumab maintenance (post-FOLFOX/CapOx induction, mCRC)REG-CAPECITABINE-CRT-CONCURRENT- Concurrent capecitabine radiosensitization (825 mg/m² PO BID on RT days only) — paired wi...REG-CAPECITABINE-PALLIATIVE- Capecitabine palliative monotherapy (CRC ECOG 3-4, BSC-adjacent low-intensity)REG-CAPOX- CAPOX (XELOX)REG-TRASTUZUMAB-CHEMO-TOGA- Trastuzumab + capecitabine + cisplatin (TOGA / KEYNOTE-811)